After the development and validation of the screening system, we leveraged this platform to identify i53 variants that display improved HDR enhancing capabilities when targeting the HBB locus, a genetic site of therapeutic relevance for the treatment of multiple hemoglobinopathies such as sickle cell anemia and β-thalassemia20–22. This evidence concerns the gene HBB and sickle cell disease.